Emanuel Della‐Torre

9.8k total citations · 2 hit papers
91 papers, 3.8k citations indexed

About

Emanuel Della‐Torre is a scholar working on Rheumatology, Epidemiology and Surgery. According to data from OpenAlex, Emanuel Della‐Torre has authored 91 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Rheumatology, 45 papers in Epidemiology and 43 papers in Surgery. Recurrent topics in Emanuel Della‐Torre's work include IgG4-Related and Inflammatory Diseases (57 papers), Neuroendocrine Tumor Research Advances (42 papers) and Gastrointestinal disorders and treatments (28 papers). Emanuel Della‐Torre is often cited by papers focused on IgG4-Related and Inflammatory Diseases (57 papers), Neuroendocrine Tumor Research Advances (42 papers) and Gastrointestinal disorders and treatments (28 papers). Emanuel Della‐Torre collaborates with scholars based in Italy, United States and France. Emanuel Della‐Torre's co-authors include John H. Stone, Marco Lanzillotta, Shiv Pillai, Hamid Mattoo, Vinay S. Mahajan, Lorenzo Dagna, Vikram Deshpande, Zachary S. Wallace, Mollie N. Carruthers and Corrado Campochiaro and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Allergy and Clinical Immunology and BMJ.

In The Last Decade

Emanuel Della‐Torre

90 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations

2014 316 citations Emanuel Della‐Torre, John H. Stone et al. Annals of the Rheumatic Diseases profile →
Advances in the diagnosis and management of IgG4 related disease

2020 172 citations Marco Lanzillotta, Gaia Mancuso et al. profile →

Peers

Countries citing papers authored by Emanuel Della‐Torre

Since Specialization

Citations

This map shows the geographic impact of Emanuel Della‐Torre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuel Della‐Torre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuel Della‐Torre more than expected).

Fields of papers citing papers by Emanuel Della‐Torre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuel Della‐Torre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuel Della‐Torre. The network helps show where Emanuel Della‐Torre may publish in the future.

Co-authorship network of co-authors of Emanuel Della‐Torre

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuel Della‐Torre. A scholar is included among the top collaborators of Emanuel Della‐Torre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuel Della‐Torre. Emanuel Della‐Torre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study 2025 ·European Journal of Internal Medicine ·Elisabetta Goni, Jens Vikse, Marco Lanzillotta, Bjørg‐Tilde Svanes Fevang, Øyvind Midtvedt, (unknown), Veronica Batani, (unknown), Georg Beyer, Lorenzo Dagna, Øyvind Molberg, Katrine Brække Norheim, Ulf Schönermarck, Ivonne Regel, Julia Mayerle, Anna‐Maria Hoffmann‐Vold, Emanuel Della‐Torre	1
2	GLP-1 agonists-induced autoimmune pancreatitis 2025 ·Drug and Therapeutics Bulletin ·(unknown), (unknown), Emanuel Della‐Torre, (unknown)	1
3	B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease 2024 ·Lara D. Veeken ·Marco Lanzillotta, Giuseppe A. Ramirez, Raffaella Milani, Lorenzo Dagna, Emanuel Della‐Torre	3
4	Association of autoimmune pancreatitis and intraductal papillary mucinous neoplasm. A retrospective analysis from a tertiary care referral center 2024 ·Pancreatology ·Marco Lanzillotta, (unknown), Giulio Belfiori, Diego Palumbo, Marco Schiavo Lena, Gabriele Capurso, Paolo Giorgio Arcidiacono, Lorenzo Dagna, Massimo Falconi, Stefano Crippa, Emanuel Della‐Torre	2
5	IgG4 in the gut: Gastrointestinal IgG4-related disease or a new subtype of inflammatory bowel disease 2024 ·Autoimmunity Reviews ·(unknown), (unknown), (unknown), Laurent Peyrin-Biroulet, Emanuel Della‐Torre, (unknown), Ferdinando D’Amico	1
6	Fibrotic phenotype of IgG4-related disease 2024 ·The Lancet Rheumatology ·Marco Lanzillotta, Emma Culver, Amita Sharma, Yoh Zen, Zhang Wen, John H. Stone, Emanuel Della‐Torre	20
7	Ustekinumab as Induction and Maintenance Therapy in Patients with Inflammatory Bowel Disease and Type II Autoimmune Pancreatitis: Report of Two Cases 2023 ·Journal of Crohn s and Colitis ·(unknown), Ferdinando D’Amico, Mariangela Allocca, Diego Palumbo, Emanuel Della‐Torre, Francesco De Cobelli, Claudio Doglioni, Paolo Giorgio Arcidiacono, Gabriele Capurso, Silvio Danese	4
8	Association of IgG4-related disease and systemic rheumatic disorders 2023 ·European Journal of Internal Medicine ·Veronica Batani, Marco Lanzillotta, (unknown), Federica Pedica, Diego Palumbo, (unknown), Paola Mapelli, Paola Bossi, Lorenzo Dagna, Emanuel Della‐Torre	7
9	Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma 2023 ·Cancers ·Sabrina Gloria Giulia Testoni, Claudia Minici, Elisa Benetti, Francesca Clemente, Daniela Boselli, Clara Sciorati, Lucia De Monte, Maria Chiara Petrone, Markus D. Enderle, (unknown), Maria Pia Protti, Angelo A. Manfredi, Francesco De Cobelli, Michele Reni, Massimo Falconi, Gabriele Capurso, Paolo Giorgio Arcidiacono, Emanuel Della‐Torre	4
10	Cardiac Safety of mRNA-Based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 2022 ·Pathogens ·Giuseppe A. Ramirez, Veronica Batani, Luca Moroni, Giacomo De Luca, (unknown), Simone Sala, Giovanni Peretto, Corrado Campochiaro, Emanuel Della‐Torre, Enrica Bozzolo, Lorenzo Dagna	3
11	Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature 2022 ·United European Gastroenterology Journal ·(unknown), Marco Lanzillotta, Nikola Panić, Torkel B. Brismar, Carlos Fernández Moro, Gabriele Capurso, Emanuel Della‐Torre, Matthias Löhr, Miroslav Vujasinović	16
12	Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study 2022 ·Nutrients ·(unknown), Giuseppe A. Ramirez, Patrizia Pignatti, (unknown), (unknown), Emanuel Della‐Torre, Daniela Breda, Samuele E. Burastero, Lorenzo Dagna, Mona‐Rita Yacoub	26
13	The role of interleukin-17 in the pathogenesis of systemic sclerosis: Pro-fibrotic or anti-fibrotic? 2021 ·Journal of Scleroderma and Related Disorders ·Silvia Bellando-Randone, Emanuel Della‐Torre, Andra Bălănescu	6
14	Clinical features and outcomes of COVID-19 in patients with IgG4-related disease: a European multi-centre study 2021 ·Lara D. Veeken ·Giuseppe A. Ramirez, Marco Lanzillotta, Mikaël Ebbo, Andreu Fernández‐Codina, Gaia Mancuso, (unknown), Lorenzo Dagna, N. Schleinitz, Fernando Martínez‐Valle, Emma Culver, Emanuel Della‐Torre	5
15	Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine 2021 ·Vaccine ·Mona‐Rita Yacoub, (unknown), (unknown), Giuseppe A. Ramirez, Emanuel Della‐Torre, Matteo Moro, (unknown), Davide Di Napoli, Alberto Ambrosio, Carlo Signorelli, Sergio L. Colombo, Luigi Beretta, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna	5
16	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study 2020 ·Annals of the Rheumatic Diseases ·Emanuel Della‐Torre, Corrado Campochiaro, Giulio Cavalli, (unknown), Angela Napolitano, (unknown), Nicola Boffini, Valentina Da Prat, Gaetano Di Terlizzi, Marco Lanzillotta, Patrizia Rovere‐Querini, Annalisa Ruggeri, Giovanni Landoni, Moreno Tresoldi, Fabio Ciceri, Alberto Zangrillo, Francesco De Cobelli, Lorenzo Dagna	187
17	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes 2020 ·Lara D. Veeken ·Marco Lanzillotta, Corrado Campochiaro, Gaia Mancuso, Giuseppe A. Ramirez, Gabriele Capurso, Massimo Falconi, Lorenzo Dagna, Emanuel Della‐Torre	57
18	Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli 2020 ·Annals of the Rheumatic Diseases ·Emanuel Della‐Torre, Corrado Campochiaro, Giulio Cavalli, (unknown), Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna	4
19	Hypersensitivity reactions to low molecular weight heparin in a pregnant woman : : case report 2015 ·Valentina Canti, Emanuel Della‐Torre	1
20	Diagnostic value of IgG4 Indices in IgG4-Related Hypertrophic Pachymeningitis 2013 ·Journal of Neuroimmunology ·Emanuel Della‐Torre, Laura Galli, Diego Franciotta, Enrica Bozzolo, Chiara Briani, Roberto Furlan, Luisa Roveri, Maria Sessa, Gabriella Passerini, Maria Grazia Sabbadini	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact